Is AZN or TMO cheaper?

On trailing earnings, TMO is cheaper: AZN trades at a 26.92 P/E and TMO at 25.80.

Which has grown faster, AZN or TMO?

Over the past five years, AZN grew revenue faster — AZN at a 16.99% CAGR versus TMO at 6.68%.

Does AZN or TMO pay a bigger dividend?

AZN yields 1.79% and TMO yields 0.28% based on trailing dividends and the latest price.

Is AZN or TMO more profitable?

AZN runs the higher net margin — AZN at 17.19% versus TMO at 15.18%.

Which has been the better investment, AZN or TMO?

Over the past 10-year, AZN delivered the higher annualized total return — AZN at 15.77% versus TMO at 12.26%. Past performance doesn't predict future results.

AstraZeneca PLC (AZN) vs Thermo Fisher Scientific Inc. (TMO)

AZN leads on 13 of 17 compared metrics, though TMO is the cheaper stock.

A side-by-side comparison of AstraZeneca PLC and Thermo Fisher Scientific Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of June 13, 2026. The ● marks the stronger figure on each row (cheaper multiple, higher margin/return).

Thermo Fisher Scientific Inc.

$174.42B

$469.34Healthcare

Total return — AZN vs TMO

growth of $100 · last 30y

AZN +723.4%TMO +1154.9%TMO compounded faster

AZN TMO

AZN vs TMO: by the numbers

•AZN is the larger company ($277.22B vs $174.42B market cap).
•TMO trades at the lower earnings multiple (25.80 vs 26.92 P/E).
•AZN converts more revenue to profit (17.19% vs 15.18% net margin).
•AZN grew revenue faster over the past five years (16.99% vs 6.68% CAGR).
•AZN pays the higher dividend yield (1.79% vs 0.28%).

Which is better, AZN or TMO?

Metric tally: AZN 13 · TMO 4

It depends on what you're optimizing for:

ValueTMO(lower P/E)

GrowthAZN(faster 5Y revenue CAGR)

IncomeAZN(higher dividend yield)

QualityAZN(higher ROIC)

Valuation

Metric	AZN	TMO
P/E ratio	26.92	25.80●
Forward P/E	15.33●	17.26
P/S ratio	4.62	3.87●
P/B ratio	5.90	3.37●
PEG ratio	0.14●	4.51
EV / EBITDA	14.92●	19.26
FCF yield	3.26%	3.86%●

Profitability

Metric	AZN	TMO
Gross margin	81.68%●	39.41%
Operating margin	23.69%●	17.76%
Net margin	17.19%●	15.18%
ROE	21.95%●	13.21%
ROIC	13.03%●	7.58%

Dividends

Metric	AZN	TMO
Dividend yield	1.79%●	0.28%
Payout ratio	48.48%	7.48%

Growth (annualized)

Metric	AZN	TMO
Revenue CAGR (5Y)	16.99%●	6.68%
EPS CAGR (5Y)	22.02%●	1.99%
FCF CAGR (5Y)	18.52%●	-0.19%
Total return CAGR (5Y)	11.03%●	0.45%

Frequently asked

Which is better, AZN or TMO?: It depends on your goal. value: TMO (lower P/E); growth: AZN (faster 5Y revenue CAGR); income: AZN (higher dividend yield); quality: AZN (higher ROIC). Across all compared metrics, AZN leads 13 to 4.
Is AZN or TMO cheaper?: On trailing earnings, TMO is cheaper: AZN trades at a 26.92 P/E and TMO at 25.80.
Which has grown faster, AZN or TMO?: Over the past five years, AZN grew revenue faster — AZN at a 16.99% CAGR versus TMO at 6.68%.
Does AZN or TMO pay a bigger dividend?: AZN yields 1.79% and TMO yields 0.28% based on trailing dividends and the latest price.
Is AZN or TMO more profitable?: AZN runs the higher net margin — AZN at 17.19% versus TMO at 15.18%.
Which has been the better investment, AZN or TMO?: Over the past 10-year, AZN delivered the higher annualized total return — AZN at 15.77% versus TMO at 12.26%. Past performance doesn't predict future results.

Go deeper

Full AZN analysis Full TMO analysis Interactive comparison tool

Dig into the metrics

AstraZeneca P/E ratio Thermo Fisher Scientific P/E ratio AstraZeneca dividend yield Thermo Fisher Scientific dividend yield AstraZeneca ROE Thermo Fisher Scientific ROE AstraZeneca operating margin Thermo Fisher Scientific operating margin AstraZeneca revenue growth Thermo Fisher Scientific revenue growth AstraZeneca free cash flow Thermo Fisher Scientific free cash flow

AstraZeneca & Thermo Fisher Scientific appear in these rankings

Fastest Revenue Growth Stocks Best 10-Year Total Return Stocks Largest Companies by Market Cap

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified June 13, 2026.